0.35
price down icon6.04%   -0.0225
after-market アフターアワーズ: .35
loading
前日終値:
$0.3725
開ける:
$0.364
24時間の取引高:
3.18M
Relative Volume:
1.58
時価総額:
$84.91M
収益:
$9.10M
当期純損益:
$-82.47M
株価収益率:
-0.6034
EPS:
-0.58
ネットキャッシュフロー:
$-72.32M
1週間 パフォーマンス:
-24.65%
1か月 パフォーマンス:
-31.28%
6か月 パフォーマンス:
-59.41%
1年 パフォーマンス:
-71.77%
1日の値動き範囲:
Value
$0.3352
$0.3742
1週間の範囲:
Value
$0.3352
$0.48
52週間の値動き範囲:
Value
$0.3352
$1.30

Vaxart Inc Stock (VXRT) Company Profile

Name
名前
Vaxart Inc
Name
セクター
Healthcare (1161)
Name
電話
(650) 550-3500
Name
住所
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
職員
0
Name
Twitter
Name
次回の収益日
2025-03-14
Name
最新のSEC提出書
Name
VXRT's Discussions on Twitter

VXRT を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
VXRT
Vaxart Inc
0.35 84.91M 9.10M -82.47M -72.32M -0.58
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Vaxart Inc Stock (VXRT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-08-15 開始されました Oppenheimer Outperform
2021-12-29 再開されました Jefferies Buy
2021-11-02 開始されました Cantor Fitzgerald Overweight
2021-06-29 ダウングレード B. Riley Securities Buy → Neutral
2021-06-24 開始されました Jefferies Buy
2021-06-11 開始されました Piper Sandler Overweight
2020-08-12 繰り返されました H.C. Wainwright Buy
2020-07-13 開始されました B. Riley FBR Buy
すべてを表示

Vaxart Inc (VXRT) 最新ニュース

pulisher
Mar 31, 2025

Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace

Mar 31, 2025
pulisher
Mar 30, 2025

RFK Jr. pauses $240 million contract for new ‘oral COVID vaccine’ - Todayville

Mar 30, 2025
pulisher
Mar 28, 2025

VAXART, INC. (VXRT) Reports Q4 Loss, Lags Revenue Estimates - MSN

Mar 28, 2025
pulisher
Mar 27, 2025

Vaxart reports inducement grants under Nasdaq listing rule - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Stock Hits 52-Week Low at $0.45 Amid Market Challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Vaxart's Major Talent Investment: 659,500 Share Awards and Key Executive Hire Signals Growth - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

B. Riley Cuts Price Target on Vaxart to $2 From $2.50, Keeps Buy Rating - Marketscreener.com

Mar 27, 2025
pulisher
Mar 24, 2025

Vaxart, Inc. (NASDAQ:VXRT) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 24, 2025
pulisher
Mar 22, 2025

Vaxart Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Mar 22, 2025
pulisher
Mar 21, 2025

Sudden Trump administration order prompts Bay Area company to lay off staff - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Bay Area biotech company lays off staff over sudden Trump admin order - SFGATE

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc to offer up to $50 mln of common stock -March 21, 2025 at 04:42 pm EDT - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

RFK Jr. paused this Peninsula company's half-billion-dollar vaccine contract, then it cut jobs - The Business Journals

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc Reports Q4 EPS of -$0.12, Missing Estimates; Revenue at $19.5 Million, Below Expectations - GuruFocus

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments ... - Yahoo Finance

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Inc (VXRT) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic Adjustments Amid Challenges - GuruFocus.com

Mar 21, 2025
pulisher
Mar 21, 2025

Vaxart Reports 2024 Financial Results and Vaccine Progress - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Vaxart, Inc. Investors of Important Deadline in Securities Class Action – VXRT - Business Wire

Mar 21, 2025
pulisher
Mar 20, 2025

Earnings call transcript: Vaxart Q4 2024 misses EPS but beats revenue - Investing.com India

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Inc. (VXRT) reports earnings - Quartz

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update And Reports Full Year 2024 Financial Results -March 20, 2025 at 04:49 pm EDT - MarketScreener

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart, Inc. SEC 10-K Report - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewswire

Mar 20, 2025
pulisher
Mar 20, 2025

Vaxart Quadruples Revenue to $28.7M as New Norovirus Vaccine Trial Launches - Stock Titan

Mar 20, 2025
pulisher
Mar 14, 2025

Pipeline - Vaxart Inc.

Mar 14, 2025
pulisher
Mar 13, 2025

Vaxart to Host Full Year 2024 Business Update and Financial Results Conference Call on March 20 - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Vaxart, Inc. to Host Conference Call for Business Update and Financial Results on March 20, 2025 - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Vaxart's Crucial 2024 Financial Update: Management to Reveal Full-Year Performance - Stock Titan

Mar 13, 2025
pulisher
Mar 11, 2025

Vaxart starts early-stage study for its pill-based vaccine for norovirus -March 11, 2025 at 08:57 am EDT - Marketscreener.com

Mar 11, 2025
pulisher
Mar 11, 2025

Vaxart Announces Clinical Trial Initiation of Norovirus Oral Pill Vaccine Candidate - GlobeNewswire

Mar 11, 2025
pulisher
Mar 11, 2025

First-Ever Norovirus Pill Vaccine Enters Clinical Trials: Vaxart's Game-Changing Approach - StockTitan

Mar 11, 2025
pulisher
Mar 11, 2025

Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Our Science - Vaxart Inc.

Mar 10, 2025
pulisher
Mar 06, 2025

Vaxart's Oral Norovirus Vaccine: Key Study Findings and Future Plans - Contagionlive.com

Mar 06, 2025
pulisher
Mar 06, 2025

Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Vaxart (VXRT) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Vaxart reports promising norovirus vaccine trial results By Investing.com - Investing.com Canada

Mar 05, 2025
pulisher
Mar 05, 2025

Vaxart reports promising norovirus vaccine trial results - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Vaxart Announces Publication Demonstrating the - GlobeNewswire

Mar 05, 2025
pulisher
Mar 05, 2025

Can Vaxart's Oral Norovirus Vaccine Overcome Age-Related Immune Challenges? New Data Says Yes - Stock Titan

Mar 05, 2025
pulisher
Mar 04, 2025

Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World

Mar 04, 2025
pulisher
Mar 04, 2025

Brother of Biden’s Top Advisor Lobbied for Biotech Firm Awarded COVID Vax Deal Halted by Kennedy - Judicial Watch

Mar 04, 2025
pulisher
Feb 27, 2025

RFK Jr. Blocks Plans to Roll Out ‘ORAL Covid Vaccine’ - substack.com

Feb 27, 2025
pulisher
Feb 27, 2025

RFK Jr issues bombshell order on Covid vaccine over safety concerns - Daily Mail

Feb 27, 2025

Vaxart Inc (VXRT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
大文字化:     |  ボリューム (24 時間):